RNS Number : 2407E
OptiBiotix Health PLC
14 May 2026

**OptiBiotix Health plc**
**("OptiBiotix" or the "Company" or "the Group")**

**SweetBiotix® Sampling**

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces plans to demonstrate its SweetBiotix products to shareholders.

The Company reported a breakthrough in the manufacture of its SweetBiotix products on 24 November 2025 leading to higher yields of purer, more concentrated, better tasting product with lower ingredient and production costs.

The Company is now in a position to demonstrate this product to shareholders at an event in London to be held in June 2026, subject to the availability of a suitable venue. In order to assess attendance and venue size, the Company would encourage all existing shareholders and prospective investors who are interested in attending to sign up (it should take less than one minute) using the link below:-

1. Visit https://optibiotix.com/s/3eda67
2. Follow the prompts on the top right hand side of the website marked SIGN UP
3. Complete your account profile (name/email address)

Once registered, OptiBiotix can update investors on location and timings and send invitations to interested shareholders. The meeting will give an overview of the commercial progress of the Company's first generation products , second generation products and their route to market, and sampling of SweetBiotix.

**For further information, please contact: OptiBiotix Health plc** www.optibiotix.com
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive

**About OptiBiotix** : www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGPUMPAUPQPUW